[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Ginguené C, Champier J, Maallem S, Strazielle N, Jouvet A, Fèvre-Montange M, Ghersi-Egea JF: P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas. Brain Pathol; 2010 Sep;20(5):926-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas.
  • Ependymomas are neuroepithelial tumors that arise from the ependymal layer bordering the cerebral ventricles and spinal canal.
  • Intracranial ependymoma represents a major encephalic tumor in children, while spinal ependymoma develops more frequently in adults.
  • To understand the pharmacoresistance that characterizes this tumoral entity, we analyzed the level of expression and localization of three major efflux transport proteins with a multidrug resistance function, P-glycoprotein, multidrug resistance-related protein 1 (MRP1) and breast cancer resistance protein (BCRP), in a series of 25 ependymomas from both children and adults.
  • Real-time-PCR analysis showed that all three genes were expressed in all tumors, with no apparent correlation between the level of expression and either age or tumor grade.
  • The MRP1 transcript was expressed at a significantly higher level in spinal tumors than in intracranial tumors.
  • The expression of the proteins corresponding to these genes was confirmed by Western blot analysis.
  • In an immunohistochemical study, P-glycoprotein and BCRP were shown to be associated with the tumoral vessels, where they presented a luminal localization, a prerequisite for their efflux drug activity into the blood.
  • These data indicate that a biochemical, transporter-dependent blood-tumor barrier may exist in ependymomas, which may reduce the tumoral bioavailability of lipophilic and amphiphilic anticancer drugs.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Blood-Testis Barrier / metabolism. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Microvessels / metabolism. Neoplasm Proteins / metabolism. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family B. ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adolescent. Adult. Aged. Child. Child, Preschool. Humans. Infant. Laminin / metabolism. Middle Aged. Models, Biological. Young Adult. von Willebrand Factor / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406235.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Laminin; 0 / Neoplasm Proteins; 0 / von Willebrand Factor
  •  go-up   go-down


2. Brisson C, Lelong-Rebel I, Mottolèse C, Jouvet A, Fèvre-Montange M, Saint Pierre G, Rebel G, Belin MF: Establishment of human tumoral ependymal cell lines and coculture with tubular-like human endothelial cells. Int J Oncol; 2002 Oct;21(4):775-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of human tumoral ependymal cell lines and coculture with tubular-like human endothelial cells.
  • Histological, immunological, and ultrastructural studies showed that the morphological features (microvilli, cilia, and caveolae) of these cultured cells were similar to those of the tumor in vivo.
  • The expression of P-gp, EGF-R, and caveolin-1 by these tumoral ependymocytes could be useful in studies on new drugs.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Culture Techniques / methods. Endothelium, Vascular / cytology. Ependymoma / pathology. Tumor Cells, Cultured
  • [MeSH-minor] Adolescent. Adult. Aged. Cells, Cultured. Child. Child, Preschool. Coculture Techniques. Collagen / pharmacology. Drug Combinations. Female. Humans. Immunohistochemistry. Infant. Laminin / pharmacology. Male. Microscopy, Electron. Microscopy, Fluorescence. Middle Aged. P-Glycoprotein / metabolism. Proteoglycans / pharmacology. Time Factors. Umbilical Veins / cytology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12239616.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / P-Glycoprotein; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


3. Moreno-Manzano V, Rodríguez-Jiménez FJ, Aceña-Bonilla JL, Fustero-Lardíes S, Erceg S, Dopazo J, Montaner D, Stojkovic M, Sánchez-Puelles JM: FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. J Biol Chem; 2010 Jan 8;285(2):1333-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results reported in this article show the discovery of FM19G11, a novel chemical entity that inhibits HIFalpha proteins that repress target genes of the two alpha subunits, in various tumor cell lines as well as in adult and embryonic stem cell models from rodents and humans, respectively.
  • FM19G11 inhibits at nanomolar range the transcriptional and protein expression of Oct4, Sox2, Nanog, and Tgf-alpha undifferentiating factors, in adult rat and human embryonic stem cells, FM19G11 activity occurs in ependymal progenitor stem cells from rats (epSPC), a cell model reported for spinal cord regeneration, which allows the progression of oligodendrocyte cell differentiation in a hypoxic environment, has created interest in its characterization for pharmacological research.
  • Arrays carried out in the presence and absence of the inhibitor showed the predominant involvement of epigenetic-associated events mediated by the drug.
  • [MeSH-major] Adult Stem Cells / metabolism. Basic Helix-Loop-Helix Transcription Factors / antagonists & inhibitors. Benzamides / metabolism. Benzoates / metabolism. Cell Differentiation / drug effects. Embryonic Stem Cells / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / antagonists & inhibitors
  • [MeSH-minor] Acetylation / drug effects. Animals. Cell Hypoxia / drug effects. Cell Hypoxia / physiology. Ependyma / cytology. Ependyma / metabolism. Gene Expression Regulation / drug effects. Gene Expression Regulation / physiology. HeLa Cells. Histones / metabolism. Homeodomain Proteins / metabolism. Humans. Male. Octamer Transcription Factor-3 / metabolism. Pharmaceutical Preparations. Rats. Rats, Sprague-Dawley. Response Elements / physiology. SOXB1 Transcription Factors / metabolism. Transcription, Genetic / drug effects. Transcription, Genetic / physiology. Transforming Growth Factor alpha / metabolism. p300-CBP Transcription Factors / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2003 Aug;14(8):3470-81 [12925778.001]
  • [Cites] Genes Dev. 2003 Jan 1;17(1):126-40 [12514105.001]
  • [Cites] Mol Interv. 2002 Jul;2(4):229-43 [14993394.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38458-65 [15247232.001]
  • [Cites] Oncogene. 1997 Jul 31;15(5):613-8 [9247316.001]
  • [Cites] Cell. 1999 Jan 8;96(1):25-34 [9989494.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2277-86 [15781641.001]
  • [Cites] Mol Ther. 2005 Jun;11(6):906-15 [15922961.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5675-86 [15964822.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W460-4 [15980512.001]
  • [Cites] Development. 2005 Aug;132(15):3393-403 [15987772.001]
  • [Cites] Biochem J. 2005 Aug 15;390(Pt 1):189-97 [15823097.001]
  • [Cites] Dev Cell. 2005 Nov;9(5):617-28 [16256737.001]
  • [Cites] Genes Dev. 2006 Mar 1;20(5):557-70 [16510872.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] J Neurosci. 2006 Nov 15;26(46):11948-60 [17108169.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2301-6 [17284606.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):335-47 [17418410.001]
  • [Cites] Cell. 2007 May 4;129(3):465-72 [17482542.001]
  • [Cites] Nat Cell Biol. 2007 Jun;9(6):625-35 [17515932.001]
  • [Cites] Neurosignals. 2006-2007;15(5):259-65 [17551265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14982-7 [17855562.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] Cell Cycle. 2007 Nov 15;6(22):2810-6 [17998805.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):90-100 [18202012.001]
  • [Cites] Cell Death Differ. 2008 Apr;15(4):678-85 [18259193.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Apr;9(4):285-96 [18285802.001]
  • [Cites] Stem Cells. 2008 Apr;26(4):920-6 [18203677.001]
  • [Cites] Ann Neurol. 2008 Apr;63(4):520-30 [18393269.001]
  • [Cites] PLoS One. 2008;3(5):e2122 [18461168.001]
  • [Cites] Nature. 2008 Jul 31;454(7204):646-50 [18594515.001]
  • [Cites] PLoS Biol. 2008 Jul 22;6(7):e182 [18651793.001]
  • [Cites] Stem Cells. 2008 Aug;26(8):2052-62 [18511603.001]
  • [Cites] Neuroscience. 2008 Aug 26;155(3):760-70 [18588947.001]
  • [Cites] J Biol Chem. 2008 Sep 12;283(37):25404-13 [18625704.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):967-75 [18987634.001]
  • [Cites] Mol Cancer Res. 2009 Apr;7(4):489-97 [19372578.001]
  • [Cites] Stem Cells. 2009 Mar;27(3):733-43 [19259940.001]
  • [Cites] J Neurosci. 2000 Oct 1;20(19):7377-83 [11007896.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(22):7812-9 [12391150.001]
  • [Cites] Nat Rev Drug Discov. 2003 Oct;2(10):803-11 [14526383.001]
  • (PMID = 19897487.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Benzamides; 0 / Benzoates; 0 / FM19G11; 0 / HIF1A protein, human; 0 / Hif1a protein, rat; 0 / Histones; 0 / Homeodomain Proteins; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / NANOG protein, human; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / Pharmaceutical Preparations; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Sox2 protein, rat; 0 / Transforming Growth Factor alpha; 0 / endothelial PAS domain-containing protein 1; EC 2.3.1.48 / p300-CBP Transcription Factors; EC 2.3.1.48 / p300-CBP-associated factor
  • [Other-IDs] NLM/ PMC2801260
  •  go-up   go-down


Advertisement
4. Preusser M, Hoischen A, Novak K, Czech T, Prayer D, Hainfellner JA, Baumgartner C, Woermann FG, Tuxhorn IE, Pannek HW, Bergmann M, Radlwimmer B, Villagrán R, Weber RG, Hans VH: Angiocentric glioma: report of clinico-pathologic and genetic findings in 8 cases. Am J Surg Pathol; 2007 Nov;31(11):1709-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiocentric glioma has recently been described as a novel epilepsy associated tumor with distinct clinico-pathologic features.
  • We report the clinical and pathologic findings in 8 additional cases of this rare tumor type and extend its characterization by genomic profiling.
  • Almost all patients had a history of long-standing drug-resistant epilepsy.
  • Cortico-subcortical tumors were located in the temporal and parietal lobes.
  • Histologically, the tumors were characterized by diffuse growth and prominent perivascular tumor cell arrangements with features of astrocytic/ependymal differentiation, but lacking neoplastic neuronal features.
  • Electron microscopy showed ependymal characteristics in 2 of 3 cases investigated.
  • In 1 of 3 cases, a high-resolution screen by array-comparative genomic hybridization identified a copy number gain of 2 adjacent clones from chromosomal band 11p11.2 containing the protein-tyrosine phosphatase receptor type J (PTPRJ) gene.
  • All patients are seizure free and without evidence of tumor recurrence at follow-up times ranging from 1/2 to 6.9 years.
  • Our findings support 2 previous reports proposing that angiocentric glioma is a novel glial tumor entity of low-grade malignancy.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / ultrastructure. Epilepsy / genetics. Gene Expression Regulation, Neoplastic. Glioma / genetics. Glioma / ultrastructure
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytes / pathology. Cell Differentiation. Cell Proliferation. Child. Child, Preschool. Chromosome Deletion. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 6. Ependyma / pathology. Europe. Female. Follow-Up Studies. Gene Dosage. Gene Expression Profiling / methods. Glial Fibrillary Acidic Protein / analysis. Humans. Magnetic Resonance Imaging. Male. Membrane Glycoproteins / analysis. Middle Aged. Mucin-1 / analysis. Nerve Growth Factors / analysis. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Receptor-Like Protein Tyrosine Phosphatases, Class 3 / genetics. S100 Calcium Binding Protein beta Subunit. S100 Proteins / analysis. Time Factors. Treatment Outcome. Vimentin / analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059228.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Membrane Glycoproteins; 0 / Mucin-1; 0 / Nerve Growth Factors; 0 / PDPN protein, human; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100B protein, human; 0 / Vimentin; EC 3.1.3.48 / PTPRJ protein, human; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 3
  •  go-up   go-down


5. Bello MJ, Alonso ME, Amiñoso C, Anselmo NP, Arjona D, Gonzalez-Gomez P, Lopez-Marin I, de Campos JM, Gutierrez M, Isla A, Kusak ME, Lassaletta L, Sarasa JL, Vaquero J, Casartelli C, Rey JA: Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res; 2004 Oct 4;554(1-2):23-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors.
  • O6-methylguanine-DNA methyltransferase (MGMT) plays a major role in repairing DNA damage from alkylating agents.
  • By removing alkyl groups from the O6-position in guanine, MGMT can prevent G:C to A:T transition mutations, a type of variation frequently involving TP53 mutations in brain tumors.
  • Promoter hypermethylation of CpG islands in tumor-related genes can lead to their transcriptional inactivation, and this epigenetic mechanism has been shown to participate in MGMT silencing in some cancers, including those affecting the nervous system.
  • To determine the relevance of defective MGMT function due to aberrant methylation in relation to the presence of TP53 mutations, we studied 469 nervous system tumors (including all major histological subtypes) for MGMT promoter methylation and TP53 mutations at exons 5-8.
  • Overall, aberrant methylation occurred in 38% of the samples (180/469), with values higher than 50% in the more malignant forms such as glioblastomas and anaplastic gliomas including those with astrocytic, oligodendroglial and ependymal differentiation.
  • In contrast, the non-glial tumors displayed an overall aberrant MGMT promoter methylation of 26%, even though this group includes highly malignant tumors such as neuroblastomas, medulloblastomas and brain metastases.
  • Overall, TP53 mutations were found in 25% of the methylated MGMT tumors (45/180), whereas only 10% of the unmethylated MGMT tumors (30/289) showed TP53 changes (P < 0.001).
  • G:C to A:T changes occurred at CpG sites in 9% of methylated tumors, and in 0.7% of the unmethylated samples.
  • This type of transition at non-CpG dinucleotides was also more frequent in the tumors with aberrant MGMT methylation (5%) than the unmethylated tumors (0.7%).
  • These data suggest that MGMT silencing as a result of promoter hypermethylation may lead to G:C to A:T transition mutations in the TP53 gene of some histological nervous system tumor subtypes.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Base Sequence. Child. Child, Preschool. DNA Primers. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15450401.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down






Advertisement